Evidence / 2025
ADHD medications dispensed, 2004–05 to 2023–24
Australian Institute of Health and Welfare (2025). AIHW mental health data.
- Population
- People in Australia dispensed ADHD medicines listed on the Pharmaceutical Benefits Scheme
- Sample
- National PBS administrative series
- Condition
- ADHD treatment dispensing
- Medication focus
- ADHD medicines listed on the PBS
- Jurisdiction
- Australia
- Last reviewed
- 1 September 2026
- Measurement period
- 2004–05 to 2023–24
Plain-language finding
The population rate of patients dispensed ADHD medicines under the PBS increased from 2 per 1,000 in 2004–05 to 22 per 1,000 in 2023–24, with much of the increase after 2018–19. This is a measure of recognised, treated demand — not a measure of underlying ADHD prevalence.
Important limitation
PBS counts people who received a listed medicine, not people who have ADHD. Private prescriptions, untreated people, and people who discontinued are not captured the same way. An eleven-fold rise in dispensing is not an eleven-fold rise in prevalence.
Why we cite this
The cleanest Australian administrative series on ADHD treatment demand. Cited to distinguish demand from prevalence.
adhd · australia · access · service-design
Supported by clinical guidelines, regulatory information, systematic reviews, or well-established pharmacological knowledge. Still describes populations, not an individual.
Claims this source supports
In Australia, ADHD assessment is constrained by clinician availability, waiting time, out-of-pocket cost, a thin public adult pathway, and regional gaps. Recognition is growing faster than the systems built to assess it.
Last reviewed 2 September 2026
Rising ADHD diagnosis and medicine dispensing in Australia are evidence of rising recognised demand. They are not, by themselves, evidence that underlying ADHD prevalence has increased by the same factor. Prevalence, recognition, diagnosis and service demand are different quantities.
This claim retains disagreement in the literature. Open the classification to read both sides.
Last reviewed 2 September 2026
More people being recognised is observable. More people seeking assessment is observable. More people receiving ADHD medication is observable. A sudden increase in the underlying prevalence of ADHD since 2020 is not currently established.
This claim retains disagreement in the literature. Open the classification to read both sides.
Last reviewed 2 September 2026